Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 1/20 | 0.58 |
| ▸ | PREP | P48147 | 3/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7284521 | 0.90 | SMN1; SMN2 (0.54) | CTSKCTSBCTSSPREPACE2 | |
| SCHEMBL11560321 | 0.87 | FKBP1A (0.57) | PREPACE2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL11489453 | 0.85 | TMEM97 (0.53) | CTSKCTSBCTSSPREPACE2 | |
| SCHEMBL7813620 | 0.84 | FKBP1A (0.53) | CTSKCTSBCTSSPREPACE2 | |
| SCHEMBL2768429 | 0.83 | PREP (0.60) | PREPACE2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL16105052 | 0.83 | FKBP1A (0.50) | CTSKCTSBCTSSPREPACE2 | |
| SCHEMBL4602471 | 0.83 | PREP (0.54) | PREPACE2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4117187 | 0.82 | SMN1; SMN2 (0.52) | PREPACE2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL13500680 | 0.82 | PREP (0.61) | CTSKCTSBCTSSPREPFKBP1A | |
| SCHEMBL13119286 | 0.82 | PREP (0.61) | CTSKCTSBCTSSPREPFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2578587-B1 | PYRAZOLE DERIVATIVES | HANDE STARLAKE BIOSCIENCE CO LTD (CN) | 2016-09-07 | — | — | EP | disclosed |
| US-9249172-B2 | Pyrazole derivatives | HANDE PHARMA LIMITED (CN) | 2016-02-02 | — | — | US | disclosed |
| US-20130142757-A1 | PYRAZOLE DERIVATIVES | HANDE STARLAKE BIOSCIENCE CO., LTD. (CN) | 2013-06-06 | — | — | US | disclosed |
| EP-2578587-A1 | PYRAZOLE DERIVATIVES | Hande Starlake Bioscience Co., Ltd. (CN) | 2013-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142757-A1 | PYRAZOLE DERIVATIVES | CBR3, CBR1, CYP2E1 | CTSK 2178/4885CTSB 2221/4885CTSS 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.